NYSE:TAK

Takeda Pharmaceutical - TAK Stock Forecast, Price & News

$13.14

+0.02 (+0.15%)

(As of 10/7/2022 04:33 PM ET)

Add

Compare

Today's Range: $13.04
▼
$13.19
50-Day Range: $12.80
▼
$14.61
52-Week Range: $12.75
▼
$15.36

Volume: 3.91 million shs
Average Volume: 2.70 million shs
Market Capitalization: $40.74 billion

P/E Ratio: 24.79
Dividend Yield: 4.19%
Price Target: $24.00

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 83.2% Upside
$24.00 Price Target
Short Interest: Healthy
0.11% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.70
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

116th out of 1,075 stocks

Pharmaceutical Preparations Industry

37th out of 537 stocks

3.3

Analyst's Opinion

Consensus Rating
Takeda Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.00, Takeda Pharmaceutical has a forecasted upside of 83.2% from its current price of $13.10.
Amount of Analyst Coverage
Takeda Pharmaceutical has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.11% of the float of Takeda Pharmaceutical has been sold short.
Short Interest Ratio / Days to Cover
Takeda Pharmaceutical has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Takeda Pharmaceutical has recently increased by 14.29%, indicating that investor sentiment is decreasing significantly.

1.7

Dividend Strength

Dividend Leadership
Takeda Pharmaceutical is a leading dividend payer. It pays a dividend yield of 4.09%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Takeda Pharmaceutical does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Takeda Pharmaceutical is 103.78%. Payout ratios above 75% are not desirable because they may not be sustainable.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TAK.

3.2

News and Social Media Coverage

News Sentiment
Takeda Pharmaceutical has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Takeda Pharmaceutical this week, compared to 3 articles on an average week.
Social Mentions This Week
MarketBeat has tracked 5 reddit mentions for Takeda Pharmaceutical this week, compared to 1 mention on an average week.
Search Interest
Only 2 people have searched for TAK on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.
Percentage Held by Institutions
Only 1.96% of the stock of Takeda Pharmaceutical is held by institutions.

3.1

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Takeda Pharmaceutical is 24.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.72.
Price to Earnings Ratio vs. Sector
The P/E ratio of Takeda Pharmaceutical is 24.72, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.69.
Price to Earnings Growth Ratio
Takeda Pharmaceutical has a PEG Ratio of 0.55. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Takeda Pharmaceutical has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

October 6, 2022 | bizjournals.com

Julie Kim advises mentees to 'take the more challenging path'

October 5, 2022 | finance.yahoo.com

U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

October 7, 2022 | Investing Trends (Ad)

The Biggest "Missing Ingredient" in the $7 Trillion EV Market

China has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.

October 5, 2022 | americanbankingnews.com

Takeda Pharmaceutical (NYSE:TAK) Sees Strong Trading Volume

September 30, 2022 | benzinga.com

The Worldwide Pharmaceutical Glycerin Based Products Industry is Expected to Reach $61.6 Billion by 2030

September 29, 2022 | marketwatch.com

Peptide Therapeutics Market Outlook, In-depth Analysis, Industry Drivers, Key Trends, Projections, and Future opportunities for the period 2022 2027

September 29, 2022 | marketwatch.com

Psoriasis Drugs Market Trends, Business Overview, Industry Growth, and Forecast 2022 To 2027

September 29, 2022 | finance.yahoo.com

Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies

October 7, 2022 | Investing Trends (Ad)

The Biggest "Missing Ingredient" in the $7 Trillion EV Market

September 28, 2022 | benzinga.com

6Short Volatility Alert: Takeda Pharmaceutical Company Limited

September 21, 2022 | markets.businessinsider.com

Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer

September 20, 2022 | finance.yahoo.com

Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatment for Adults with Post-Transplant Cytomegalovirus (CMV) infection

September 19, 2022 | finance.yahoo.com

Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States

September 16, 2022 | markets.businessinsider.com

Takeda: Maribavir Gets Positive CHMP Opinion To Treat Post-transplant Cytomegalovirus Refractory

September 16, 2022 | marketwatch.com

Takeda's Drug to Battle Post-Transplant Virus Recommended for Marketing Approval by EU

September 16, 2022 | finance.yahoo.com

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

September 15, 2022 | finance.yahoo.com

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

September 14, 2022 | finance.yahoo.com

Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease

September 13, 2022 | finance.yahoo.com

Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries

September 8, 2022 | finance.yahoo.com

Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors

September 8, 2022 | seekingalpha.com

Takeda: The Current Price Makes No Sense

September 7, 2022 | benzinga.com

BFS Syringes Market to Exceed US$ 1,973 Mn by 2032 as Automation Becomes the Key for Packaging Manufacturers | Future Market Insights, Inc.

September 7, 2022 | finance.yahoo.com

Takeda Canada Partners with the Canadian Institutes of Health Research (CIHR) to Advance Research in Rare Diseases

September 6, 2022 | marketwatch.com

Asparaginase Market size Analysis by Geography Highlighting the Consumption in the Globe As Well As Indicating the Factors | 108 Pages Report

September 6, 2022 | nasdaq.com

Takeda Pharmaceutical Becomes Oversold (TAK)

September 1, 2022 | finance.yahoo.com

The Petri Dish: Takeda ends Finch deal, Bain buys Waltham manufacturer

August 30, 2022 | finance.yahoo.com

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Last Earnings: 7/28/2022
Today: 10/07/2022
Next Earnings (Estimated): 10/27/2022
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:TAK
CUSIP: N/A
CIK: 1395064
Web: www.takeda.com
Phone: (166) 204-2111
Fax: 813-3278-2268
Employees: 47,347
Year Founded: 1781

Price Target and Rating

Average Stock Price Forecast: $24.00
High Stock Price Forecast: $24.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +82.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.53
Trailing P/E Ratio: 24.79
Forward P/E Ratio: 5.84
P/E Growth: 0.55
Net Income: $2.05 billion
Net Margins: 5.43%
Pretax Margin: 6.08%
Return on Equity: 12.41%
Return on Assets: 5.35%

Debt

Debt-to-Equity Ratio: 0.68
Current Ratio: 1.18
Quick Ratio: 0.75

Sales & Book Value

Annual Sales: $31.79 billion
Price / Sales: 1.28
Cash Flow: $3.49 per share
Price / Cash Flow: 3.76
Book Value: $16.31 per share
Price / Book: 0.81

Miscellaneous

Outstanding Shares: 3,100,722,000
Free Float: 3,099,482,000
Market Cap: $40.74 billion
Optionable: Optionable
Beta: 0.69

Social Links

Key Executives

Mr. Christophe Weber (Age 56)
Pres, CEO & Representative Director
Comp: $4.29M

Mr. Constantine Saroukos (Age 51)
CFO & Representative Director
Comp: $2.56M

Dr. Andrew S. Plump (Age 57)
Pres of R&D and Representative Director
Comp: $2.43M

Dr. Seigo Izumo
Chair of Management Board

Mr. Haruhiko Hirate (Age 65)
Member of Management Board

Salvatore Alesci
Member of Management Board and Head of R&D Global Science & Biomedical Policy

Norimasa Takeda
Chief Accounting Officer & Corp. Controller

Mr. Iwaaki Taniguchi
Sr. VP of Corp. Fin. & Controlling Department

Mr. Gabriele Ricci (Age 44)
Chief Data & Technology Officer

Mr. Christopher David O'Reilly
Global Head of Investor Relations & Global Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings or view top-rated stocks.
What is Takeda Pharmaceutical's stock price forecast for 2022?: 4 analysts have issued twelve-month price targets for Takeda Pharmaceutical's stock. Their TAK share price forecasts range from $24.00 to $24.00. On average, they expect the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 82.9% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.
How have TAK shares performed in 2022?: Takeda Pharmaceutical's stock was trading at $13.63 at the beginning of the year. Since then, TAK stock has decreased by 3.7% and is now trading at $13.12.
View the best growth stocks for 2022 here.
When is Takeda Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our TAK earnings forecast.
How were Takeda Pharmaceutical's earnings last quarter?: Takeda Pharmaceutical Company Limited (NYSE:TAK) issued its earnings results on Thursday, July, 28th. The company reported $0.56 earnings per share for the quarter. The firm earned $7.51 billion during the quarter. Takeda Pharmaceutical had a trailing twelve-month return on equity of 12.41% and a net margin of 5.43%.
Is Takeda Pharmaceutical a good dividend stock?: Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.55 per share and currently has a dividend yield of 4.09%. TAK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 103.78%. Payout ratios above 75% are not desirable because they may not be sustainable.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?: Takeda Pharmaceutical updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $3.74-$3.74 for the period. The company issued revenue guidance of $28.49 billion-$28.49 billion.
What other stocks do shareholders of Takeda Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).
What is Takeda Pharmaceutical's stock symbol?: Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."
How do I buy shares of Takeda Pharmaceutical?: Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Takeda Pharmaceutical's stock price today?: One share of TAK stock can currently be purchased for approximately $13.12.
How much money does Takeda Pharmaceutical make?: Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $40.68 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.53 on an earnings per share basis.
How many employees does Takeda Pharmaceutical have?: The company employs 47,347 workers across the globe.
Does Takeda Pharmaceutical have any subsidiaries?: The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?: Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Takeda Pharmaceutical - TAK Stock Forecast, Price & News

Takeda Pharmaceutical MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Social Mentions This Week

Search Interest

MarketBeat Follows